Enzyme immunoassay of human Epidermal Growth Factor Receptor (hEGFR)

Rajnish, Kumar; Meenakshi, A.; Sivakumar, N.

doi:10.3233/hab-2001-103-406

Cited by 18 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous reports about the levels of sEGFR in healthy individuals showed discrepant values, ranging from 4.5 to 159.1 ng ml À1 (Choi et al, 1997;Hoffmann et al, 2001;Markopoulos et al, 2001;Ramesh Kumar et al, 2001;Carney et al, 2002;Baron et al, 2003;Kong et al, 2004;Gokhale et al, 2005). Even using the same commercial ELISA kit, the differences are remarkable: 36.4 ng ml À1 , in our study, vs 74.8 ng ml À1 reported by Baron et al (2001).…”

Section: Discussioncontrasting

confidence: 53%

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

et al. 2007

View full text Add to dashboard Cite

Serum levels of the soluble epidermal growth factor receptor (sEGFR) and its ligands epidermal growth factor (EGF), transforming growth factor-a (TGF-a) and amphiregulin (AR) were measured in healthy donors and patients with non-small cell lung cancer (NSCLC) and head and neck carcinoma (HNC). In NSCLC, we found sEGFR and EGF levels significantly lowered in patients with respect to healthy donors. In HNC patients, significantly diminished levels were found in the case of sEGFR, EGF and also AR. In both malignancies, no significant association was found between the serum levels of the molecules and the patients' gender, age or smoking habit. Only a significant association was found between the decrease of sEGFR and the absence of distant metastasis in NSCLC and the tumour stage in HNC. The most interesting result was that combining sEGFR and EGF, sensitivities of 88% in NSCLC and 100% in HNC were reached without losing specificity (97.8% in both cases). The use of discriminant analysis and logistic regression improved the sensitivity for NSCLC and the specificity for HNC. These data demonstrate a potentially interesting value of the serum levels of sEGFR and EGF, especially when combined, as markers for NSCLC and HNC.

show abstract

Section: Discussioncontrasting

confidence: 53%

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

et al. 2007

View full text Add to dashboard Cite

show abstract

“…7 Protein expression may also be quantified by western blotting 4 or enzyme immunoassay (EIA). 8 The latter technique measures total receptor protein in tumor specimens, irrespective of the expressing cell type or cellular localization. EGFR protein levels in serum from breast cancer patients have been examined using EIA 8 and been reported to be markedly elevated in 67.5% of patients.…”

Section: Methods Of Assessment Of Epidermal Growth Factor Receptor Exmentioning

confidence: 99%

Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer

Rampaul

Pinder²,

Nicholson³

et al. 2005

Advances in Anatomic Pathology

View full text Add to dashboard Cite

EGFR expression in primary breast cancer has been extensively investigated for its prognostic and predictive value. However overall there is no consensus on its potential to guide such prognostication. This is largely because of the great heterogeneity in study designs and methods used to assay the EGFR protein. The impetus to standardize such studies is much needed as there are now several tyrosine kinase inhibitors directed against the EGF receptor and phase II trials are showing significant promise.

show abstract

“…Its range between primary diagnostic step and metastatic diagnostic step is from about 11 to 30 ng/mL and in women with breast cancer is up to 270 ng/mL (Kumar et al 2001). The proposed immunosensor (dynamic range: 1-40 ng/mL) covers just the critical concentration range of the EGFR in serum samples.…”

Section: Analytical Applicationmentioning

confidence: 97%

Electrochemical aptamer/antibody based sandwich immunosensor for the detection of EGFR, a cancer biomarker, using gold nanoparticles as a signaling probe

Ilkhani

Sarparast

Noori

et al. 2015

Biosensors and Bioelectronics

167

View full text Add to dashboard Cite

Enzyme immunoassay of human Epidermal Growth Factor Receptor (hEGFR)

Cited by 18 publications

References 9 publications

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer

Electrochemical aptamer/antibody based sandwich immunosensor for the detection of EGFR, a cancer biomarker, using gold nanoparticles as a signaling probe

Contact Info

Product

Resources

About